Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

The prostatic middle lobe: clinical significance, presentation and management

Nature Reviews Urology volume 20, pages 645–653 (2023)Cite this article

Subjects

Abstract

The role of the prostatic middle lobe in the presentation and management of benign prostatic hyperplasia (BPH) is under-appreciated. Middle lobe enlargement is associated with intravesical prostatic protrusion (IPP), which causes a unique type of bladder outlet obstruction (BOO) via a ‘ball-valve’ mechanism. IPP is a reliable predictor of BOO and the strongest independent factor for failure of medical therapy necessitating conversion to surgical intervention. Men with middle lobe enlargement tend to exhibit mixed symptoms of both the storage and the voiding types, but symptomatology will vary depending on the degree of IPP present. Initial assessments such as uroflowmetry and post-void residual volumes are inadequate to detect IPP and could confound the clinical picture. Radiological evaluation of prostate morphology is key to assessment as it provides important prognostic information and can help with operative planning. Treatment strategies employed for BPH should consider the shape and morphology of prostate adenomata, specifically the presence of middle lobe enlargement and the degree of associated IPP.

Key points

  • Various subcategories of benign prostatic hyperplasia exist, specifically, middle lobe enlargement is associated with intravesical prostatic protrusion (IPP), which causes a unique type of bladder outlet obstruction (BOO) via a ball-valve mechanism.

  • IPP is a reliable clinical parameter that positively correlates strongly with the urodynamic evidence of BOO.

  • Measurement of IPP using transabdominal or transrectal ultrasonography is a discriminative evaluation that can help inform the decision to use invasive urodynamic studies.

  • Low-grade IPP can be managed conservatively with α-adrenoceptor antagonists and/or 5α-reductase inhibitors; 5α-reductase inhibitors might reduce total prostate volume but are unlikely to alter the degree of IPP.

  • High-grade IPP is the strongest predictor of failed medical therapy and conversion to surgical intervention. Patients with high-grade IPP should be offered surgery from the outset to reduce the risk of clinical progression.

  • The extent, shape and morphology of IPP might help inform the optimal surgical approach; however, more studies are needed to examine their effects on the success of bladder outlet procedures.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The enlarged middle lobe of the prostate acts as a ball valve obstructing the bladder.
Fig. 2: Classic uroflowmetry pattern in a patient with middle lobe enlargement.
Fig. 3: Radiological evidence of middle lobe enlargement.

Similar content being viewed by others

References

  1. Platz, E. A., Smit, E., Curhan, G. C., Nyberg, L. M. & Giovannucci, E. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in US men. Urology 59, 877–883 (2002).

    Article  PubMed  Google Scholar 

  2. Foo, K. T. Solving the benign prostatic hyperplasia puzzle. Asian J. Urol. 3, 6–9 (2016).

    Article  PubMed  Google Scholar 

  3. Goddard, J. C. History of the prostate, part two: the cause of urinary symptoms. Trends Urol. Men. Health 10, 31–34 (2019).

    Article  Google Scholar 

  4. Hunter, J. A Treatise on the Venereal Disease (1788).

  5. Oesterling, J. E. Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate 29, 67–73 (1996).

    Article  Google Scholar 

  6. Chia, S. J., Heng, C. T., Chan, S. P. & Foo, K. T. Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int. 91, 371–374 (2003).

    Article  CAS  PubMed  Google Scholar 

  7. Gandhi, J. et al. Clinical considerations for intravesical prostatic protrusion in the evalutation and management of bladder outlet obstruction secondary to benign prostatic hyperplasia. Curr. Urol. 12, 6–12 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lee, A. et al. Can intravesical prostatic protrusion predict bladder outlet obstruction even in men with good flow? Asian J. Urol. 3, 39–43 (2016).

    Article  PubMed  Google Scholar 

  9. Sigdel, G. & Belokar, W. Clinical significance of intravesical prostatic protrusion in patients with benign prostatic hyperplasia. J. Univ. Coll. Med. Sci. 3, 6–10 (2015).

    Article  Google Scholar 

  10. Luo, G. C., Foo, K. T., Kuo, T. & Tan, G. Diagnosis of prostate adenoma and the relationship between the site of prostate adenoma and bladder outlet obstruction. Singap. Med. J. 54, 482–486 (2013).

    Article  Google Scholar 

  11. Randall, A. Surgical pathology of prostatic obstructions (Williams & Wilkins, 1931).

  12. Guneyli, S. et al. Magnetic resonance imaging of benign prostatic hyperplasia. Diagn. Interv. Radiol. 22, 215–219 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Lee, H. J., Lee, A., Huang, H. H., Sundaram, P. & Foo, K. T. Patients with small prostates and low-grade intravesical prostatic protrusion – a urodynamic evaluation. Asian J. Urol. 4, 247–252 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  14. Wasserman, N. F. Benign prostatic hyperplasia: a review and ultrasound classification. Radiol. Clin. North. Am. 44, 689–710 (2006).

    Article  PubMed  Google Scholar 

  15. Wesson, M. B. The prostatic median bar. J. Urol. 22, 397–406 (1929).

    Article  Google Scholar 

  16. Wang, D., Huang, H., Law, Y. M. & Foo, K. T. Relationships between prostatic volume and intravesical prostatic protrusion on transabdominal ultrasound and benign prostatic obstruction in patients with lower urinary tract symptoms. Ann. Acad. Med. Singap. 44, 60–65 (2015).

    Article  PubMed  Google Scholar 

  17. Tan, Y. G. et al. A systematic review and meta-analysis of transabdominal intravesical prostatic protrusion assessment in determining bladder outlet obstruction and unsuccessful trial without catheter. Eur. Urol. Focus. 8, 1003–1014 (2022). This systematic review provides evidence that IPP is a reliable clinical parameter that correlates strongly with underlying BOO and unsuccessful trial without catheter.

    Article  PubMed  Google Scholar 

  18. Doo, C. K. & Uh, H. S. Anatomic configuration of prostate obtained by noninvasive ultrasonography can predict clinical voiding parameters for determining BOO in men with LUTS. Urology 73, 232–236 (2009).

    Article  PubMed  Google Scholar 

  19. Roehrborn, C. G. et al. Five year results of the prospective randomized controlled prostatic urethral LIFT study. Can. J. Urol. 24, 8802–8813 (2017).

    PubMed  Google Scholar 

  20. McVary, K. T. et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 195, 1529–1538 (2016).

    Article  PubMed  Google Scholar 

  21. Zorn, K. C. et al. Aquablation therapy in large prostates (80–150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3‐year trial results. BJUI Compass 3, 130–138 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  22. Eure, G., Rukstalis, D. & Roehrborn, C. Prostatic urethral lift for obstructive median lobes: consistent results across controlled trial and real-world settings. J. Endourol. 37, 50–59 (2023).

    Article  PubMed  Google Scholar 

  23. Lee, S. W., Cho, J. M., Kang, J. Y. & Yoo, T. K. Clinical and urodynamic significance of morphological differences in intravesical prostatic protrusion. Korean J. Urol. 51, 694–699 (2010). IPP has two morphological types of trilobar and bilobar enlargement; bladder contractility and BOO indexes were significantly increased in the trilobar adenoma group compared with the bilobar adenoma group.

    Article  PubMed  PubMed Central  Google Scholar 

  24. D’Ancona, C. et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol. Urodyn. 38, 433–477 (2019).

    Article  PubMed  Google Scholar 

  25. Stravodimos, K. G. et al. TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative workup? Int. Urol. Nephrol. 41, 767–771 (2009).

    Article  PubMed  Google Scholar 

  26. Kuo, T. L., Teo, J. S. & Foo, K. T. The role of intravesical prostatic protrusion (IPP) in the evaluation and treatment of bladder outlet obstruction (BOO). Neurourol. Urodyn. 35, 535–537 (2016).

    Article  PubMed  Google Scholar 

  27. Lieber, M. M. et al. Intravesical prostatic protrusion in men in Olmsted County, Minnesota. J. Urol. 182, 2819–2824 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  28. Kwon, S. Y., Ryu, J. W., Choi, D. H. & Lee, K. S. Clinical significance of the resistive index of prostatic blood flow according to prostate size in benign prostatic hyperplasia. Int. Neurourol. J. 20, 75–80 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  29. Shin, S. H., Kim, J. W., Oh, M. M. & Moon, D. G. Defining the degree of intravesical prostatic protrusion in association with bladder outlet obstruction. Korean J. Urol. 54, 369–372 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  30. Reis, L. O., Barreiro, G. C., Baracat, J., Prudente, A. & D’Ancona, C. A. Intravesical protrusion of the prostate as a predictive method of bladder outlet obstruction. Int. Braz. J. Urol. 34, 627–637 (2008).

    Article  PubMed  Google Scholar 

  31. Rieken, M., Presicce, F., Autorino, R. & DE Nuzio, C. Clinical significance of intravesical prostatic protrusion in the management of benign prostatic enlargement: a systematic review and critical analysis of current evidence. Min. Urol. Nefrol. 69, 548–555 (2017).

    Google Scholar 

  32. Yoshida, T. et al. Intravesical prostatic protrusion as a predicting factor for the adverse clinical outcome in patients with symptomatic benign prostatic enlargement treated with dutasteride. Urology 91, 154–157 (2016). The 3-year cumulative incidence of AUR or BPH-related surgery in the low IPP group was 9.9% compared with 71.5% in the high IPP group.

    Article  PubMed  Google Scholar 

  33. Zheng, J. et al. Role for intravesical prostatic protrusion in lower urinary tract symptom: a fluid structural interaction analysis study. BMC Urol. 15, 86 (2015). This fluid structural interaction analysis study demonstrated how high grades of IPP cause increasing distortion and deformation of the prostatic urethra leading to deterioration of flow efficiency and compromise of BOO alleviation treatment.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kim, J. H. et al. Terminal dribbling in male patients with lower urinary tract symptoms: relationship with International Prostate Symptom Score and with intravesical prostatic protrusion. BMC Urol. 15, 89 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  35. Abrams, P. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 21, 167–178 (2002).

    Article  PubMed  Google Scholar 

  36. Bates, C. P., Whiteside, C. G. & Turner‐Warwick, R. Synchronous cine/pressure/flow/cysto‐urethrography with special reference to stress and urge incontinence. Br. J. Urol. 42, 714–723 (1970).

    Article  CAS  PubMed  Google Scholar 

  37. Shafik, A., El-Sibai, O. & Ahmed, I. Effect of urethral dilation on vesical motor activity: identification of the urethrovesical reflex and its role in voiding. J. Urol. 169, 1017–1019 (2003).

    Article  PubMed  Google Scholar 

  38. Lu, S. Y., Yang, C.-M., Fan, Y.-H., Long Lin, A. T. & Chen, K.-K. Intravesical prostatic protrusion correlates well with storage symptoms in elderly male patients with non-neurogenic overactive bladder. Urol. Sci. 27, 17–20 (2016).

    Article  Google Scholar 

  39. Steers, W. D. Pathophysiology of overactive bladder and urge urinary incontinence. Rev. Urol. 4, S7–S18 (2002).

    PubMed  PubMed Central  Google Scholar 

  40. Keqin, Z. et al. Clinical significance of intravesical prostatic protrusion in patients with benign prostatic enlargement. Urology 70, 1096–1109 (2007).

    Article  PubMed  Google Scholar 

  41. Hur, W. S. et al. Predictors of urgency improvement after holmium laser enucleation of the prostate in men with benign prostatic hyperplasia. Investig. Clin. Urol. 57, 431–436 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  42. Kim, J. W. et al. Intravesical prostatic protrusion is a risk factor for bladder stone in patients with benign prostatic hyperplasia. Urology 84, 1026–1029 (2014).

    Article  PubMed  Google Scholar 

  43. Huang, W. et al. Risk factors for bladder calculi in patients with benign prostatic hyperplasia. Medicine 96, e7728 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  44. Roehrborn, C. G. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology 51, 19–22 (1998).

    PubMed  Google Scholar 

  45. Dujin, M., Hovius, M. C. & Boeve, L. M. S. Intravesical protrusion of giant median prostatic lobe: a case report. Urol. Case Rep. 44, 102152 (2022).

    Article  Google Scholar 

  46. Park, H. K. et al. Effect of intravesical prostatic protrusion on the characteristics of lower urinary tract symptom change after 12-week drug medication: a prospective analysis. Low. Urin. Tract. Symptoms 5, 1–4 (2013).

    Article  PubMed  Google Scholar 

  47. Cumpanas, A. A., Botoca, M., Minciu, R. & Bucuras, V. Intravesical prostatic protrusion can be a predicting factor for the treatment outcome in patients with lower urinary tract symptoms due to benign prostatic obstruction treated with tamsulosin. Urology 81, 859–863 (2013).

    Article  PubMed  Google Scholar 

  48. Kalkanli, A. et al. Intravesical prostatic protrusion: a potential marker of alpha-blocker treatment success in patients with benign prostatic enlargement. Urology 88, 161–165 (2016).

    Article  PubMed  Google Scholar 

  49. Topazio, L. et al. Intravescical prostatic protrusion is a predictor of alpha blockers response: results from an observational study. BMC Urol. 18, 6 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Liu, Q., Zhu, Y., Liu, J., Qi, J. & Kang, J. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH). Int. Urol. Nephrol. 49, 399–404 (2017).

    Article  CAS  PubMed  Google Scholar 

  51. Hirayama, K. et al. Evaluation of intravesical prostatic protrusion as a predictor of dutasteride-resistant lower urinary tract symptoms/benign prostatic enlargement with a high likelihood of surgical intervention. Urology 86, 565–569 (2015). In patients with BPH and severe IPP, combination therapy with dutasteride might have insufficient efficacy owing to a low proportion of stromal components, necessitating conversion to surgical intervention.

    Article  PubMed  Google Scholar 

  52. Dantas, L. P. et al. Treatment of bladder dysfunction with solifenacin: is there a risk of dementia or cognitive impairment? Braz. J. Med. Biol. Res. 55, e11721 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. McVary, K. T., Rogers, T. & Roehrborn, C. G. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology 126, 171–179 (2019).

    Article  PubMed  Google Scholar 

  54. McVary, K. T. & Roehrborn, C. G. Three-year outcomes of the prospective, randomized controlled Rezūm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology 111, 1–9 (2018).

    Article  PubMed  Google Scholar 

  55. Rukstalis, D. et al. Prostatic urethral lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate Cancer Prostatic Dis. 22, 411–419 (2019).

    Article  PubMed  Google Scholar 

  56. Gravas, S. et al. EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO) (European Association of Urology, 2020).

  57. Parsons, J. K., Dahm, P., Kohler, T. S., Lerner, L. B. & Wilt, T. J. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2020. J. Urol. 204, 799–804 (2020).

    Article  PubMed  Google Scholar 

  58. Eure, G. et al. Real-world evidence of prostatic urethral lift confirms pivotal clinical study results: 2-year outcomes of a retrospective multicentre study. J. Endourol. 33, 576–584 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  59. Naidu, S. G. et al. Prostate artery embolization–review of indications, patient selection, techniques and results. J. Clin. Med. 10, 5139 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  60. Bilhim, T. Prostatic artery embolization and the median lobe: stuck in the middle with you? J. Vasc. Interv. Radiol. 30, 1817–1819 (2019).

    Article  PubMed  Google Scholar 

  61. Yu, S. C. H. et al. Thickness-to-height ratio of intravesical prostatic protrusion predicts the clinical outcome and morbidity of prostatic artery embolization for benign prostatic hyperplasia. J. Vasc. Interv. Radiol. 30, 1807–1816 (2019). IPP with a thickness to height ratio of ≤1.3 predicts the occurrence of post-procedure complications with urinary obstruction in patients undergoing PAE for the treatment of LUTS.

    Article  PubMed  Google Scholar 

  62. Maron, S. Z. et al. Effect of median lobe enlargement on early prostatic artery embolization outcomes. J. Vasc. Interv. Radiol. 31, 370–377 (2020).

    Article  PubMed  Google Scholar 

  63. Meira, M. et al. Intravesical prostatic protrusion does not influence the efficacy of prostatic artery embolization. J. Vasc. Interv. Radiol. 32, 106–112 (2019).

    Article  Google Scholar 

  64. Gilling, P., Anderson, P. & Tan, A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. J. Urol. 197, 1565–1572 (2017).

    Article  PubMed  Google Scholar 

  65. Roehrborn, C. G., Teplitsky, S. & Das, A. K. Aquablation of the prostate: a review and update. Can. J. Urol. 26, 20–24 (2019).

    PubMed  Google Scholar 

  66. Gilling, P. et al. WATER: a double-blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. J. Urol. 199, 1252–1261 (2018).

    Article  PubMed  Google Scholar 

  67. Young, M. J., Elmussareh, M., Morrison, T. & Wilson, J. R. The changing practice of transurethral resection of the prostate. Ann. R. Coll. Surg. Engl. 100, 326–329 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. DeLay, K. J., Nutt, M. & McVary, K. T. Ejaculatory dysfunction in the treatment of lower urinary tract symptoms. Transl. Androl. Urol. 5, 450–459 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  69. Favilla, V. et al. Risk factors of sexual dysfunction after transurethral resection of the prostate (TURP): a 12 months follow-up. J. Endocrinol. Invest. 36, 1094–1098 (2013).

    Article  CAS  PubMed  Google Scholar 

  70. Gul, Z., Chughtai, B., Te, A. E., Thomas, D. & Kaplan, S. A. Ejaculatory preserving middle lobe only-transurethral resection and vaporization of the prostate: 12-year experience. Urology 134, 199–202 (2019).

    Article  PubMed  Google Scholar 

  71. Gilling, P. J., Kennett, K., Das, A. K., Thompson, D. & Fraundorfer, M. R. Holmium laser enucleation of the prostate (HOLEP) combined with transurethral tissue morcellation: an update on the early clinical experience. J. Endourol. 12, 457–459 (1998).

    Article  CAS  PubMed  Google Scholar 

  72. Tamalunas, A. et al. Holmium laser enucleation of the prostate: a truly size-independent method? Low. Urin. Tract. Symptoms 14, 17–26 (2022).

    Article  PubMed  Google Scholar 

  73. Rücker, F. et al. A call for HoLEP: en-bloc vs. two-lobe vs. three-lobe. World J. Urol. 39, 2337–2345 (2021).

    Article  PubMed  Google Scholar 

  74. Ito, K. et al. Intravesical prostatic protrusion is not always the same shape: evaluation by preoperative cystoscopy and outcome in HoLEP. Neurourol. Urodyn. 37, 2160–2166 (2018). Patients with middle lobe protrusion had greater IPSS improvement after HoLEP than those with comparable-length IPP but without middle lobe protrusion.

    Article  PubMed  Google Scholar 

  75. Wisenbaugh, E. S., Nunez-Nateras, R., Mmeje, C. O., Warner, J. N. & Humphreys, M. R. Does prostate morphology affect outcomes after holmium laser enucleation? Urology 81, 844–848 (2013).

    Article  PubMed  Google Scholar 

  76. Humphreys, M. R. et al. Holmium laser enucleation of the prostate–outcomes independent of prostate size? J. Urol. 180, 2431–2435 (2008).

    Article  PubMed  Google Scholar 

  77. Oh, S. J. Current surgical techniques of enucleation in holmium laser enucleation of the prostate. Investig. Clin. Urol. 60, 333–342 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Guy’s and St Thomas’ NHS Foundation Trust, London, UK

    Sammy Gharbieh, Fairleigh Reeves & Ben Challacombe

Authors
  1. Sammy Gharbieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fairleigh Reeves
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ben Challacombe
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

S.G. researched data for the article. S.G. and B.C. contributed substantially to discussion of the content. S.G. and F.R. wrote the article. All authors reviewed and/or edited the manuscript before submission.

Corresponding author

Correspondence to Sammy Gharbieh.

Ethics declarations

Competing interests

The authors declare no completing interests.

Peer review

Peer review information

Nature Reviews Urology thanks Jonathan Goddard, Giuseppe Magistro and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gharbieh, S., Reeves, F. & Challacombe, B. The prostatic middle lobe: clinical significance, presentation and management. Nat Rev Urol 20, 645–653 (2023). https://doi.org/10.1038/s41585-023-00774-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-023-00774-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing